Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOral - PhysicianPharm

Relationship between amyloid and tau levels and its impact on tau spreading

Vincent Dore, Natasha Krishnadas, Pierrick Bourgeat, Kun Huang, Shenpeng Li, Samantha Burnham, Colin Masters, Jurgen Fripp, Victor Villemagne and Christopher Rowe
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 116;
Vincent Dore
1Csiro Heidelberg Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Natasha Krishnadas
2Austin Hospital Heidelberg Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pierrick Bourgeat
3CSIRO Herston Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kun Huang
2Austin Hospital Heidelberg Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shenpeng Li
1Csiro Heidelberg Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samantha Burnham
1Csiro Heidelberg Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Colin Masters
4The Florey Institute of Neuroscience and Mental He Melbourne Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jurgen Fripp
1Csiro Heidelberg Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Victor Villemagne
5Austin Health Heidelberg Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher Rowe
6Austin Hospital Melbourne Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

116

Purpose: Previous studies have shown that Aβ-amyloid (Aβ) likely promotes tau to spread beyond the medial temporal lobe. However, the Aβ levels necessary for tau to spread in the neocortex is still unclear.

Methods: 466 participants underwent tau imaging with [18F]MK6420 and Aβ imaging with [18F]NAV4694. Aβ scans were quantified on the Centiloid (CL) scale with a cut-off of 25CL for abnormal levels of Aβ (A+). Tau scans were quantified in three regions of interest (ROI) (mesial temporal (Me); temporoparietal neocortex (Te); and rest of neocortex (R)) and four mesial temporal region (entorhinal cortex, amygdala, hippocampus and parahippocampus) using the cerebellar cortex as reference region. Regional tau thresholds were established as the 95%ile of the cognitively unimpaired A- subjects. The prevalence of abnormal tau levels (T+) along the Centiloid continuum was determined.

Results: The plots of prevalence of T+ show earlier and greater increase along the Centiloid continuum in the medial temporal area compared to neocortex. Prevalence of T+ was low but associated with Aβ level between 10-40 CL reaching 23% in Me, 15% in Te and 11% in R. Between 40-70 CL, the prevalence of T+ subjects per CL increased four-fold faster and at 70 CL was 64% in Me, 51% in Te and 37% in R. In cognitively unimpaired, there were no T+ in R below 50 CL. The highest prevalence of T+ was found in the entorhinal cortex, reaching 40% at 40 CL and 80% at 60 CL.

Conclusions: Outside the entorhinal cortex, abnormal levels of cortical tau on PET are rarely found with Aβ levels below 40 CL. Above 40 CL prevalence of T+ accelerates in all areas. Moderate Aβ levels are required before neocortical tau becomes detectable.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 62, Issue supplement 1
May 1, 2021
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Relationship between amyloid and tau levels and its impact on tau spreading
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Relationship between amyloid and tau levels and its impact on tau spreading
Vincent Dore, Natasha Krishnadas, Pierrick Bourgeat, Kun Huang, Shenpeng Li, Samantha Burnham, Colin Masters, Jurgen Fripp, Victor Villemagne, Christopher Rowe
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 116;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Relationship between amyloid and tau levels and its impact on tau spreading
Vincent Dore, Natasha Krishnadas, Pierrick Bourgeat, Kun Huang, Shenpeng Li, Samantha Burnham, Colin Masters, Jurgen Fripp, Victor Villemagne, Christopher Rowe
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 116;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oral - PhysicianPharm

  • Using an assumed lung mass underestimates the lung absorbed dose in patients undergoing 90Y radioembolization therapy
  • Safety and efficacy of radioligand therapy with 177lutetium-PSMA-617 within 3 months after 223Radium-dichloride
  • Usefulness of99mTc SESTAMIBI Scintigraphy in Persistent Hyperparathyroidism after Kidney Transplant
Show more Oral - PhysicianPharm

Novel Radiotracers and Multi-Modal Imaging of the Brain

  • Aspirin blockade of COX-1 in human organs is reduced by plasma as shown by PET imaging and blood assays with 11C-PS13
  • [11C]Deschloroclozapine is an improved PET radioligand for quantifying a human muscarinic DREADD expressed in monkey brain
  • Kinetic modeling of novel radiotracers for the GABA Transporter-1 in nonhuman primates
Show more Novel Radiotracers and Multi-Modal Imaging of the Brain

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire